Molecular Partners out-licenses therapeutic protein

Molecular Partners AG is set to receive $45 million upfront from Allergan Inc for the exclusive global rights to a therapeutic protein in Phase 2 development for the treatment of retinal diseases. The molecule targets VEGF-A.